Truist Securities Maintains Buy on CVS Health, Raises Price Target to $118

Benzinga Newsdesk www.benzinga.com Positive 76.9%

Neg 0% Neu 0% Pos 76.9%

Truist Securities analyst David Macdonald maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $108 to $118.